Following treatment with nivolumab, a programmed death (PD)-1 inhibitor, the expression of inflammatory markers seems to correlate with better survival and treatment response in hepatocellular carcinoma (HCC) patients, a recent study has shown. This suggests that antitumour inflammatory mechanisms play a role in the action of nivolumab.
Avoiding sugar in the diet may help prevent cancer, particularly breast, suggests a recent study, contributing to the debate of the implementation of sugar taxation, marketing regulation, and other sugar-related policies.
Survival and clinical outcomes in patients with advanced stage endometrial cancer are comparable among the different sequences of adjuvant chemotherapy and radiation therapy, a recent study has shown. However, “sandwich” therapy results in less chronic toxicity, which provides an opportunity for a better quality of life in survivorship.
Among inflammatory bowel disease (IBD) patients with a current or prior malignancy, treatment with vedolizumab or antitumour necrosis factor (anti-TNF) does not bear an increased hazard of developing new or recurrent cancer, as shown in a study.
High genomic score, prostate-specific antigen (PSA) kinetics, and PSA density ≥0.15 are predictive of biopsy reclassification within 3 years of commencing active surveillance, according to a study. Moreover, the association of PSA kinetics and PSA density ≥0.15 with reclassification persists at 5 years following diagnosis.
CPX-351, a liposomal encapsulation of cytarabine and daunorubicin, is safe and effective in elderly patients with secondary acute myeloid leukaemia, leading to remission and improving patient response to allogeneic stem cell transplantation, a recent study has found.
A negative magnetic resonance imaging (MRI) following an initial negative MRI-guided biopsy is unlikely to lead to clinically significant prostate cancer and repeat biopsy, suggests a study. However, repeat MRI-guided biopsy is needed when lesions are seen on follow-up MRI.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.